New York University

The General Hospital Corporation

American Biosciences, Inc.

Massachusetts Institute of Technology

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

National Institutes of Health

Paul L Huang

Sylvia Lee-Huang

Philip L Huang

Peter Huang

Hao-Chia Chen

Hsiang-fu Kung

Henry I Huang

Michael A Moskowitz

Mark C Fishman

John Z H Zhang

Young Tae Chang

Ju Bao

Yongtao Sun

Dawei Zhang

Jae Wook Lee

Michael John Cima

Peter L Nara

Christophoros Christou Vassiliou

Yibo Ling

Terrence Pong

Philip Lin Huang

An implantable magnetic relaxation sensor is provided that comprises superparamagnetic nanoparticies functionalized with one or more agents that bond with a biomarker of interest. The sensor is configured for minimally-invasive implantation into a human or animal, and is configured to indicate the implanted sensor's cumulative exposure to the biomarker of interest by analysis using magnetic resonance relaxometry.

Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker

The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPAR&#x3b3;2, LPL and &#x3b1;P2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus

Methods described herein relate to mitochondria and their role in Human immunodeficiency virus type 1 (HIV-1) infection and cell-to-cell HIV-1 transmission and compositions and methods for modulating mitochondrial mediated cell-to-cell transmission of HIV-1. Methods for screening to identify inhibitors of mitochondrial mediated cell-to-cell transmission of HIV-1 are also envisioned herein.

Mitochondria and human immunodefiency virus type 1

A fragment of lysozyme which contains a minimum nine amino acid sequence with antiviral, anti-tumor and bactericidal activities but lacking muramidase activity is provided. The invention also relates to pharmaceutical compositions containing this fragment and methods for treating HIV infection or for inhibiting tumor growth using this fragment as an active ingredient.

Anti-HIV and anti-tumor peptides and fragments of lysozyme

This invention relates to transgenic non-human animals comprising a disrupted endothelial nitric oxide synthase gene. These animals exhibit abnormal wound-healing properties and hypertension. This invention also relates to methods of using the transgenic animals to screen for compounds having a potential therapeutic utility for vascular endothelial disorders, such as hypertension, cerebral ischemia or stroke, atherosclerosis and wound-healing activities. Moreover, this invention also relates to methods of treating a patient suffering from hypertension and wound-healing abnormalities with the compounds identified using the transgenic animals, and methods of making the transgenic animals. A method of treating a wound using nitroglycerin is also provided.

Endothelial NOS transgenic animals and methods of use

Endothelial NOS knockout mice and methods of use

A new protein, termed TAP 29, obtainable from the root tuber of the plant Trichosanthes kirilowii or produced by recombinant means is useful for treating HIV infections or tumors. In treating HIV infections, the protein is administered alone or in conjunction with conventional AIDS therapies. Also provided are processes for purifying the protein, DNA sequences encoding the protein, hosts expressing the protein, recombinant DNA methods for expressing the protein, and antibodies specific for the protein.

Anti-HIV protein, TAP 29, from tricosanthes, DNA coding therefor and

A protein, in particular MAP 30, obtainable from both the fruit and seeds of Momordica charantia or produced by recombinant means useful for treating tumors and HIV infections is disclosed. In treating HIV infections, the protein is administered alone or in conjunction with conventional AIDS therapies. Also provided are processes for purifying the protein, DNA sequences encoding the protein, and recombinant DNA methods for expressing the protein.

Plant protein useful for treating tumors and HIV infection

New proteins, termed GAP 31, obtainable from the seeds of Gelonium multiflorum, and DAP 30 and DAP 32, obtainable from the leaves or seeds of Dianthus caryophyllus, or the above proteins produced by recombinant means, are useful for treating HIV infections. In treating HIV infections, the protein is administered alone or in conjunction with other anti-HIV therapeutics. Also provided are processes for purifying the proteins, DNA sequences encoding the proteins, hosts expressing the proteins, recombinant DNA methods for expressing the proteins, and antibodies specific for the proteins.

Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof

Growing community of inventors

Boston, MA, United States of America

Paul L Huang